Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

10.11.2026

GLP-1 Eye Risk: FDA Orders New Warnings

The FDA orders GLP-1 eye risk warnings for diabetes and weight-loss medicines after reviewing NAION evidence. Read what the changes mean for care.
GLP-1 eye risk warning highlights rare optic nerve condition linked to potential vision loss
Image | Life Collection Photo | Adobe Stock/2238586075

GLP-1 eye risk has prompted the US Food and Drug Administration (FDA) to require new warnings across medicines with GLP-1 receptor activity.

Announced on 9 November, the changes concern non-arteritic anterior ischaemic optic neuropathy (NAION), a rare condition that can cause permanent sight loss. Manufacturers must include the potential increased risk in prescribing information’s warnings and precautions section.

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

More from Health Matters

08.11.2026

Xtandi Patent Dispute Heads to Constitutional Court

The Xtandi patent dispute reaches South Africa’s Constitutional Court on 23 November. Read what is at stake for generic access and damages claims.

06.11.2026

Pharmaceutical Sovereignty Put to the Test by Ebola

Pharmaceutical sovereignty is back in focus as Ebola spreads in the DRC. See how pooled procurement and shared regulation could secure supplies.

05.11.2026

Rare Disease Funding in Focus After KeyHealth Ruling

Rare disease funding is under scrutiny after the KeyHealth ruling. See how schemes could share the cost of treatments such as Ultomiris.